Ascendiant Capital Markets Lowers Vivos Therapeutics (NASDAQ:VVOS) Price Target to $5.50

Vivos Therapeutics (NASDAQ:VVOS) had its price target dropped by equities researchers at Ascendiant Capital Markets from $6.50 to $5.50 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price indicates a potential upside of 168.29% from the stock’s current price.

Several other research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 10th. HC Wainwright began coverage on shares of Vivos Therapeutics in a report on Monday, November 17th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $4.92.

Vivos Therapeutics Trading Down 3.8%

NASDAQ VVOS opened at $2.05 on Wednesday. Vivos Therapeutics has a 12 month low of $1.98 and a 12 month high of $7.95. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 3.31. The stock’s fifty day moving average price is $2.71 and its 200-day moving average price is $3.48. The stock has a market cap of $18.43 million, a P/E ratio of -1.16 and a beta of 6.88.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings results on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%. The company had revenue of $6.78 million for the quarter, compared to analysts’ expectations of $4.49 million. As a group, equities analysts forecast that Vivos Therapeutics will post -1.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Vivos Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Vivos Therapeutics during the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. purchased a new stake in Vivos Therapeutics during the second quarter valued at $220,000. Finally, Connective Capital Management LLC bought a new position in Vivos Therapeutics in the third quarter valued at about $620,000. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.